# A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

> **NCT05911763** · — · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 200 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Efanesoctocog Alfa BIVV001

## Key facts

- **NCT ID:** NCT05911763
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-30
- **Primary completion:** 2028-06-06
- **Final completion:** 2030-09-17
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911763, "A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05911763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*